[a]https%3A%2F%2Fwww.beilupharma.com%2Fproducts%2Fmri-contrast-media%2F[/a] <br> <br>#gadopentetate #dimeglumine <br> <br>Magnetic resonance imaging Contrast Media (MRI intravenous Contrast Media), also called Magnetic resonance imaging Contrast Agents, which is Gadolinium based contrast agent (GBCA), mainly refers to: after being introduced into the body through a certain way (generally intravenous injection), the contrast agent used in mri can produce more obvious image contrast between interest range and surrounding tissues. Different from the iodinated Contrast Media of CT/X-ray, the contrast material for mri acts indirectly by affecting the proton relaxation time of the molecule. When entering the blood vessels and tissues of the gadolinium-containing Contrast Media in the body, the contrast media used in mri products can shorten the relaxation time of T1 to enhance image contrast. The classic mr contrast media has wide indications, high detection rate, high safety and cost-effectiveness. <br> <br>Different types of mri contrast <br>Gadopentetate Dimeglumine Injection/API <br>Gadopentetate Dimeglumine Injection is the first domestic Gadolinium Contrast Media launched in China by Beilu Pharma in 1992. It has the same safety efficacy as the original product, but more cost-effective. Beilu Pharma offer MRI agents with specifications of 469mg/ml 10ml, 12ml, 15ml, 20ml. <br>Gadobutrol Injection/API <br>Gadobutrol Injection is a Macrocyclic Gadolinium Contrast Media, which is more stable and not easy to release gadolinium than the Linear type Contrast-enhanced magnetic resonance imaging ( MRI ) of the brain and spinal cord, and contrast-enhanced magnetic resonance angiography ( CE-MRA ). Beilu Pharma offer products with specifications of 604.72mg/ml 7.5m. <br> <br>Gadobenate Dimeglumine Injection <br>Paramagnetic Contrast Media for diagnostic magnetic resonance imaging ( MRI ) of the liver and central nervous system. Beilu Pharma offer 10ml specification. <br> <br>Ferric Ammonium Citrate Effervescent Granules <br>Oral magnetic resonance Contrast Media. This type of MRI contrast media can significantly improve the images quality of MRCP and MRU, and can also be used as a positive contrast agent for the digestive tract. Beilu Pharma offer specifications: 3g: 0.6g ( Fe 129mg ), 6g: 1.2g ( Fe 258mg ). <br> <br> <br>Safety of Gadolinium Contrast Media <br> <br>Acute reactions <br>Gadolinium Contrast Media possess a very low incidence ( &lt; 2.5 % ) of acute adverse reactions compared to many other drugs. Almost all of their reactions are very mild, the most common are nausea, headache, discomfort at the injection site, vomiting, metallic taste, paresthesia, fever and dizziness. <br> <br>Immediate hypersensitivity reactions may occur within 1 hour of imaging agents administration, it is approximately 1 in 1000 cases. These are more likely to occur in patients with allergies, asthma, and allergic reactions to gadolinium contrast agents. The most common of these reactions are mild pruritus ( itching ) and urticarial ( hives ). The moderate hypersensitivity reactions occur in about 1 in 5000 cases, it usually includes bronchospasm, facial oedema, arrhythmias, laryngospasm, tachycardia, or widespread urticarial(hives). <br> <br>The incidence of severe reactions is about 1 in 20,000. A number of severe anaphylactoid reactions to Gd MRI Contrast Media, including death, have been reported worldwide, the risk of death is about 1 in 400,000. <br> <br>Chronic ReactionsMRI Contrast Media-Chronic reactions <br>NSF ( Nephrogenic Systemic Fibrosis ) is the most famous of Chronic reactions to Ga Contrast Media. It is a disease of fibrosis of the skin and internal organs, which occurs in patients with chronic severe renal insufficiency. Several hundred patients have been diagnosed worldwide since the first reported case in 2006. NSF has now been largely eliminated as an existing disease with the efforts of the biology community. However, Gd-containing plaques in the extremities have been reported and may represent a forme fruste of NSF. <br> <br>The US FDA believes that although medical literature reports that there is the deposition of gadolinium-containing Contrast Media in the brain tissue of some patients undergoing 4 or more MRI scans, so far, there are no harmful symptoms, signs, and pathological changes appearing associated with the gadolinium-based contrast agent deposition in brain tissue. In its database of adverse event reporting system, the FDA has received many adverse event reports of patients experiencing pain or other symptoms after single or multiple applications of gadolinium-containing Contrast Media. However, so far, the FDA hasn&#039;t been able to clarify common features in these reports. It is not proven yet that the reported symptoms are reasonably related to gadolinium. Further information is needed to evaluate the possible risks caused by gadolinium deposition. <br> <br>In conclusion, although the incidence of adverse reactions of the gadolinium Contrast Media used in the MRI enhancement examination is very low, one should always keep in mind that any drug administration carries with it the risk of life-threatening reaction, and long-term risks of gadolinium contrast medium deposition must be considered. <br> <br>As one of the most professional contrast media companies, beijing beilu pharmaceutical co ltd provides glimepiride and contrast dye, gadopentetate dimeglumine and etc. Want to know more, contact us.

[a]https%3A%2F%2Fwww.beilupharma.com%2Fproducts%2Fioversol.html[/a] <br> <br>#Ioversol <br> <br>Ioversol <br>CAS No.: 87771-40-2 <br>Molecular formula: C18H24I3N3O9 <br>Molecular Weight: 807.11 <br>Quality standard: CP, USP <br>Characteristics: White or almost white powder <br>Content (HPLC): ≥99.0% <br>Packing: 25KG, 50KG/drum <br>Storage: Protected from light, sealed tightly <br> <br>If you need any kinds of contrast medium, please contact us, as a professional contrast media manufacturing companies, Bei lu is willing to offer you high quality products.

[a]https%3A%2F%2Fwww.beilupharma.com%2Fproducts%2Fiopamidol-intermediate.html[/a] <br> <br>#Beilu <br> <br>CAS No.: 35453 19 1 <br>Molecular formula: C8H4I3NO4 <br>Molecular weight: 558.84 <br>Quality standard: CP, USP <br>Content (HPLC): ≥99.0% <br>Packing: 25KG, 50KG/drum <br>Storage: Protected from light, sealed tightly <br> <br>Beilu, as an excellent contrast media manufacturer, offers a wide range of ct contrast media for you to choose from.

#iopamidol #370 <br>[a]https%3A%2F%2Fwww.beilupharma.com%2Fproducts%2Fiopamidol-injection.html[/a] <br> <br> <br>Iopamiro injection is the second-generation non-ionic iodinated Contrast Media launched in the global market. In 2015, Beilu firstly launched and listed iopamidol 370 Injection, one of the most widely used types of contrast medium in the Chinese market.  <br>Product name: Iopamidol Injectionnon <br>Generic name: Iopamidol Injection <br>Type: Injectable Contrast Media for CT/X-ray <br>Ingredients: Iopamidol <br>Specification: <br>(1) 50ml: 15 gl <br>(2) 100ml: 30 gl <br>(3) 50ml: 18.5 gl <br>(4) 100ml: 37 gl <br>Administration: Intravascular injection <br>Adverse reactions: The application of organic iodine compounds can cause adverse reactions, as well as allergic or drug-induced shock. See the details from the package insert <br>Shelf life: 36 months <br> <br>Advantages of iopamidol 300 Injection <br>High enhancement value, which increased the contrast between the lesion and solid organs, improved the lesion detection. <br>Low viscosity <br>Low osmotic pressure <br>Low injection speed, which reduces vascular pressure and prevents contrast media extravasation (patient with poor tolerance, such as children, elderly, diabetes or tumor patients, are more suitable for high-concentration contrast media) <br>The low total dosage of Contrast media <br>Low radiation dose <br> <br>Indications of Iopamidol Injection <br>Neuroradiology: Spinal nerve root angiography, Cisternography and ventriculography. <br>Angiography: Cerebral arteriography, Coronary angiography, Thoracic aorta and abdominal aorta angiography, Angiocardiography, Selectivevisceral arteriography, Peripheral arteriography and venography, Digital subtraction angiography of cerebral arteries, peripheral arteries and abdominal arteries. <br>Urinary system angiography: Venous urography, Enhanced scan in CT examination, Arthrography, Fistula angiography, Digital subtraction angiography. <br>Precautions please refer to the package insert.

#iohexol #brand #name <br>[a]https%3A%2F%2Fwww.beilupharma.com%2Fproducts%2Fiohexol-injection.html[/a] <br> <br>What is iohexol <br>Iohexol oral is one of the different types of contrast media. Compared with a traditional ionic Contrast Media, Iohexol Injection has an excellent molecular structure and it can greatly improve user safety and significantly reduce adverse reactions.  The iodinated contrast agent has excellent clinical feedback and good imaging results. In 1998, iohexol 300 Injection was launched as Beilu&#039;s 1st iodinated Contrast Media. <br>Product name: Iohexol Injection <br>Generic name: Iohexol Injection <br>Type: Injectable Contrast Media for CT/X-ray <br>Ingredients: Iohexol <br>Specification: <br>(1) 20 ml: 6 gI         (2) 50 ml: 15 gI <br>(3) 75 ml: 22.5 gI    (4) 100 ml: 30 gI <br>(5) 20 ml: 7 gI         (6) 50 ml: 17.5 gI <br>(7) 100 ml: 35 gI <br>Administration: For injection or oral use of iodinated contrast <br>Adverse reactions: See the details from the package insert <br>Shelf life: 36 months <br> <br>Indications of Iohexol Injection <br>The omnipaque iohexol is an X-ray contrast agent. It can be used for angiocardiography, arteriography, urography, enhanced CT examination inclduing cervical, thoracic and lumbar myelography, CT cisternography following intrathecal injection (i.e., an injection into the subarachnoid space); arthrography, endoscopic retrograde cholangiopancreatography (ERCP), herniography or fistulography, hysterosalpingography, sialography, percutaneous transhepatic cholangiography (PTC), sinography, gastroenterography, T-tube angiography, etc. <br>Precautions of Iohexol Injection <br>General precautions for the use of nonionic-monomer contrast agent: <br>1. Special attention should be paid to patients with allergies, asthma and adverse reactions to iodinated contrast agents. Prophylactic medications such as steroids and H1/H2 histamine receptor antagonists may be considered for these patients. <br>2. The risk of serious reactions related to this type of CT contrast agent is low. However, iodinated contrast agents can provoke anaphylactoid reactions or other allergic reactions. Therefore, first aid measures should be trained in advance, and necessary rescue drugs and devices should be prepared for possible serious reactions. <br>3. In view of the low accuracy of pre-test in predicting allergic reactions caused by nonionic contrast agents and the possibility that the pre-test itself may lead to serious allergic reactions, it is not recommended to use pretest to predict iodine allergic reactions. <br>4. Venous access should be kept smooth throughout the X-ray examination. <br>5. In the in-vitro tests, the effect of nonionic contrast agents on the coagulation system is lighter than that of ionic contrast agents. During angiography, great care should be taken in the intravascular technical procedures, and the catheter should be irrigated with heparinized saline from time to time to reduce the thrombosis and embolism related to the technical procedures. <br>6. Patients, especially patients with multiple myeloma, diabetes, renal insufficiency, infants and young children, and the elderly, must be appropriately hydrated before and after the use of contrast agent. Electrolyte disturbance and hemodynamic disorders are common in infants (&lt; 1 year old), particularly neonates. Special attention should be paid to patients with serious heart diseases and pulmonary arterial hypertension because they are prone to developing hemodynamic disorders and cardiac rhythm disturbances. <br>7. Patients with acute encephalopathy, brain tumour or history of epilepsy should be prevented from seizures, and special attention should be paid to them. The risks of seizures and neurologic reactions are significantly increased in patients with alcohol or drug abuse. Transient hearing loss or deafness occurs in a few patients after myelography, which is possibly caused by a decrease in CSF pressure after lumbar puncture. <br>8. In view of the high risks of acute renal failure after the use of contrast agent, special attention should be paid to patients with pre-existing renal impairment and diabetes and patients with atypical globulinemia (multiple myelomatoses and Waldenstrom macroglobulinemia). <br>9. Preventive actions include: <br>Identify patients with high-risk factors. <br>Ensure patients are appropriately hydrated and, if necessary, the infusion may be maintained intravenously prior to examination until the contrast agent is cleared from the kidneys. <br>Avoid any nephrotoxic agent, oral gallbladder contrast agent, surgery for arterial occlusion, renal angioplasty or other major surgeries that increase the renal burden until the contrast agent is cleared. <br>Repeat radiographic testing is delayed until renal function returned to the pre-examination level. <br>To prevent lactic acidosis, the level of serum creatinine must be determined before intravascular injection of iodinated contrast agent into diabetic patients taking metformin. For patients with abnormal serum creatinine/renal function, metformin must be discontinued and the examinations with contrast agent must be postponed until after 48 hours of discontinuation. Metformin should be reused only after renal function and serum creatinine level are constant. In some emergency cases of patients with abnormal or unknown renal function, the physician must assess both advantages and disadvantages of using contrast agent and take precautions, such as discontinuation of metformin, adequate hydration of patients, testing of renal functions, and careful observation of symptoms of lactic acidosis. <br>There is a potential risk of transient hepatic dysfunction. Special attention should be paid to patients with serious hepatic and renal insufficiency due to significantly longer time to clear contrast agent. Hemodialysis patients may receive the examinations with contrast agents. Immediate hemodialysis is not necessary after the injection of contrast agent because there is no evidence showing that hemodialysis can protect patients with renal impairment from contrast-induced nephropathy. <br>Iodinated contrast agents may exacerbate symptoms of myasthenia gravis. Patients with pheochromocytoma should be treated with α-blockers to prevent hypertensive crisis in interventional procedures. Special attention should also be paid to patients with hyperthyroidism. Patients with multinodular goitre may develop hyperthyroidism after using iodinated contrast agents. The possibility of transient hypothyroidism in preterm infants after using contrast agents should be clearly recognized. <br>Contrast media extravasation (CME) occasionally causes localized pain or oedema, which gradually subsides without sequelae. However, inflammation and even tissue necrosis may occasionally occur. Routine treatment is to elevate the affected limb and cold-compress at local sites. Surgical decompression is required in case of compartment syndrome. <br>10. Observation time: <br>Patients should be observed for at least 30 minutes after the use of the contrast agent because most serious adverse reactions occur during this period. However, there is still the possibility of a delayed response. <br>11. Intraspinal injection: <br>After myelography, patients should rest for 1 h with 20°-raised head and chest. Patients can carefully get out of bed and walk without bending over. If patients are still in bed, keep their head and chest raised for 6 hours. Patients with low seizure thresholds should be closely monitored during this period, and outpatients should not stay alone for the first 24 hours. <br>12. Effects on the ability to drive vehicles and operate machines: <br>Do not drive a vehicle or operate a machine within 24 hours after intraspinal injection. <br>13. As with all non-gastrointestinal drugs, this product should be visually inspected before use to check for particulate matter, discoloration and container damage. <br>This type of Iohexol contrast agent should be drawn into the barrel before use. Each vial is for single use only, and the unused portion should be discarded. <br> <br>For more information about iohexol brand name and omnipaque package insert, please feel free to contact us! <br> <br>Beijing beilu pharmaceutical co ltd firstly launched and listed Iopamidol Injection, one of the most widely used types of contrast medium in the Chinese market.

#visipaque #package #insert <br>[a]https%3A%2F%2Fwww.beilupharma.com%2Fproducts%2Fiodixanol-injection.html[/a] <br> <br>Iodixanol Injection is a visipaque contrast media that is isotonic with plasma. It has excellent cardiac safety and renal safety, which is most comfortable to use, especially suitable for high risk patients. Gadopentetate iodixanol visipaque is also available here. <br> <br>Product name: Iodixanol Injection <br>Generic name: Iodixanol Injection <br>Type: visipaque package insert for CT/X-ray <br>Ingredients: visipaque 320 <br>Specification: <br>(1)100ml-27 gl <br>(2)50ml-16 gl <br>(3)100ml-32 gl <br>Administration: For Intravascular use only <br>Adverse reactions: See the details from the package insert <br>Shelf life: 24 months <br> <br>Beilu also produces visipaque package insert with high quality and reasonable price, contact us for more info!

Glimepiride 1 tablet is a sulfonylurea hypoglycemic drug that can be used in combination with insulin. In 2001, Glimepiride tablets (Dibei), as the first hypoglycemic product of beijing pharmaceuticals, was first listed in China and belongs to the second class of national new drugs. <br> <br>Product name: Glimepiride Tablets <br>Specifications: glimepiride tab 1mg×30 tablets；glimepiride 2 mg×15 tablets；glimepiride 2 tablet×30 tablets <br>Characteristics: White tablet <br> <br>Indications : <br>As one of the oral antidiabetic drugs produced by Beilu Pharma, our glimepiride tablets are only suitable for type 2 diabetes that cannot fully control blood sugar through diet control, exercise therapy and weight loss. <br>Glimepiride tablets are not suitable for type 1 diabetes (for example, the treatment of diabetic patients with a history of ketoacidosis), diabetic ketoacidosis or Treatment of pre-diabetic coma or coma. <br>Usage and Dosage: Please refer to the package insert <br>Adverse reactions, Contraindications, Precautions: Please refer to the package insert. <br>Storage: Shade, seal, and keep in a dry place. <br>Packaging: Aluminum plastic packaging, 15 pills/plate, 1 plate/box; 15 pills/plate, 2 plates/box. <br>Shelf life: 24 months <br> <br>Advantages of Glimepiride Tablets <br>Double effect directly hit the hypoglycemic core <br>Double effect: Glimepiride tablets can promote insulin secretion and improve insulin resistance. At the same time, it can improve the two major pathophysiological abnormalities of insulin secretion and insulin resistance in patients with type 2 diabetes. <br>Efficiently reduce postprandial blood glucose, fasting blood glucose and glycosylated haemoglobin <br>Glimepiride tablets monotherapy can comprehensively reduce FPG PPG and HbA1c in newly diagnosed T2DM patients <br>Combination therapy, such as combined metformin, acarbose, etc., has a more significant overall hypoglycemic effect <br>Less hypoglycemia, less weight impact, high safety <br>Short-term treatment, the risk of glimepiride hypoglycemia is only 1/3 of that of Glibenclamide <br>Long-term treatment, the risk of glimepiride hypoglycemia is only 1/7of that of Glibenclamide <br>Glimepiride has a small impact on the weight of T2DM patients <br>Once a day to improve patient compliance <br>If the patient&#039;s compliance is poor, Glimepiride tablets should be selected, once a day. <br> <br>For more information about side effects of glimepiride 1mg tablet and glimepiride 2mg tablets used for, please feel free to contact us! <br>#glimepiride#1#tablet <br>[a]https%3A%2F%2Fwww.beilupharma.com%2Fproducts%2Fglimepiride-tablets.html[/a]

Since Gadopentetate Dimeglumine Injection was launched in 1992 by Beilu Pharma in China, it was highly recommended and accepted by the radiologist, and quickly occupied the market with its excellent quality and reasonable price. Up to now, linear gadolinium has been safely used for nearly 30 years, with excellent enhancement effects and few side effects. Beilu also produces gadobutrol injection with high quality and reasonable price, contact us for more info! <br> <br>Product name: Gadopentetate Dimeglumine Injection <br>Generic name: Gadopentetate Dimeglumine Injection <br>Type: Injectable Contrast Media for MRI, Linear Contrast Media <br>No.1 market share in China <br>Ingredients: Gadopentetate Dimeglumine <br>Specification: 10ml:4.69 g; 12ml:5.63 g; 15ml:7.04 g; 20ml:9.38 g <br>Posology and method of administration: Intravenous injection <br>Adverse reactions: See the details from the package insert <br>Shelf life: 36 months <br> <br>Indication of Gadopentetate Dimeglumine Injection <br>Magnetic resonance imaging of the central nervous system (brain and spinal cord), abdomen, chest, pelvis, limbs and other human organs and tissues. <br>Precautions of Gadopentetate Dimeglumine Injection <br>1. Use with caution in patients with severe kidney damage, epilepsy, hypotension, asthma and other allergic respiratory diseases and those with allergic tendencies. <br>2. Take care to avoid the extravasation of the gadopentetic acid liquid during injection to prevent tissue pain. <br>3. The serum iron and bilirubin levels of some patients will increase slightly after medication, but they are asymptomatic and can return to normal within 24 hours. <br>4. Pregnant women and breastfeeding women should use it with caution. Animal experiments show that a small amount of medicine liquid enters the milk. <br>5. The effective enhancement time of Magnevist contrast is 45 minutes. MRI examination should be performed immediately after intravenous injection. <br>6. The remaining medicine liquid after one examination should not be used again. <br>7. When applying this type of MRI contrast media, follow the relevant safety regulations in magnetic resonance imaging. <br>8. GBCAs should be used with caution. When plain scan MRI cannot obtain the corresponding vital diagnostic information, GBCAs can be used, and the lowest approved dose is used as much as possible. <br>9. Gadolinium deposition <br>Current evidence shows that after repeated use of GBCAs, trace amounts of gadolinium can remain in the brain and other body tissues. Research reports have shown that multiple uses of GBCAs can increase the intensity of brain signals, especially in the dentate nucleus and globus pallidus. Currently, there are more reports about linear GBCAs and fewer reports about macrocyclic GBCAs. Animal experiments have shown that the amount of gadolinium deposited after repeated use of linear GBCAs is higher than that of repeated use of macrocyclic. <br>The clinical significance of brain gadolinium deposition is unclear. <br>In order to minimize the potential risks associated with gadolinium deposition in the brain, it must be used in strict accordance with the indications and approved doses. It is recommended to use the lowest approved dose that meets the requirement of diagnosis and perform a careful benefit-risk assessment and patient informed communication before repeated administration. <br>#Gadopentetate#Dimeglumine#Injection <br>[a]https%3A%2F%2Fwww.beilupharma.com%2Fproducts%2Fgadopentetate-dimeglumine-injection-api%2F[/a]

In 2020, Beilu launched its macrocyclic Contrast Media- Gadobutrol Injection, it is gadolinium-based non-ionic Contrast Media, a paramagnetic Contrast Media used in various parts of the body lesion (including the brain and spinal cord) MRI imaging and angiography examination. Its macrocyclic nature ensures it is well-tolerated with a good safety profile for MRI Contrast. As a professional contrast media manufacturer, Beilu can provide you with the high concentration gadobutrol gadovist that leads to a better image with lower volume. We also provide DTPA acid with high quality. <br> <br>Product name: Gadobutrol Injection <br>Generic name: Gadobutrol Injection <br>Type: Injectable Contrast Media for MRI, Macrocyclic Contrast Media <br>Ingredients: Gadobutrol <br>Specification: gadovist 7.5 ml : 4.5354 g <br>Administration: Intravenous administration only. <br>Adverse reactions: See the details from the package insert. <br>Shelf life: 24 months <br> <br>Indication of Gadopentetate Dimegumine Injection <br>Magnetic resonance imaging of the central nervous system (brain and spinal cord), abdomen, chest, pelvis, limbs and other human organs and tissues. <br> <br>Precautions of Gadopentetate Dimegumine Injection <br>1. Use with caution in patients with severe kidney damage, epilepsy, hypotension, asthma and other allergic respiratory diseases and those with allergic tendencies. <br>2. Pay attention to avoid the extravasation of the liquid during the gadobutrol injection uses so as to prevent tissue pain. <br>3. The serum iron and bilirubin levels of some patients will increase slightly after medication, but they are asymptomatic and can return to normal within 24 hours. <br>4. Pregnant women and breastfeeding women should use it with caution. Animal experiments show that a small amount of medicine liquid enters the milk. <br>5. The effective enhancement time of this product is 45 minutes. MRI examination should be performed immediately after intravenous injection. <br>6. The remaining medicine liquid after one examination should not be used again. <br>7. When applying the gadovist dose, follow the relevant safety regulations in magnetic resonance imaging. <br>8. GBCAs should be used with caution. When plain scan MRI cannot obtain the corresponding vital diagnostic information, GBCAs can be used, and the lowest approved dose is used as much as possible. <br>9. Gadolinium deposition <br> <br>Current evidence shows that after repeated use of GBCAs, trace amounts of gadolinium can remain in the brain and other body tissues. Research reports have shown that multiple uses of GBCAs can increase the intensity of brain signals, especially in the dentate nucleus and globus pallidus. Currently, there are more reports about linear GBCAs and fewer reports about macrocyclic GBCAs. Animal experiments have shown that the amount of gadolinium deposited after repeated use of linear GBCAs is higher than that of repeated use of macrocyclic. <br>The clinical significance of brain gadolinium deposition is unclear. <br>In order to minimize the potential risks associated with gadolinium deposition in the brain, it must be used in strict accordance with the indications and approved doses. It is recommended to use the lowest approved dose that meets the requirement of diagnosis and perform a careful benefit-risk assessment and patient informed communication before repeated administration. <br>#gadobutrol#injection#uses <br>[a]https%3A%2F%2Fwww.beilupharma.com%2Fproducts%2Fgadobutrol-Injection-api.html[/a]